Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma

February 6, 2009 updated by: GERCOR - Multidisciplinary Oncology Cooperative Group

Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well neoadjuvant radiation therapy and capecitabine work in treating patients who are undergoing surgery for stage III or stage IV colorectal adenocarcinoma.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary

  • Determine the objective tumor response rate in patients with stage III or IV colorectal adenocarcinoma treated with neoadjuvant radiotherapy and capecitabine.

Secondary

  • Determine the tolerance profile of this regimen in these patients.
  • Determine the rate of preservation of functional integrity of the anal sphincter in patients treated with this regimen.
  • Compare the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral capecitabine twice daily and undergo concurrent radiotherapy 5 days a week on weeks 1-5. Patients undergo surgery on week 6.

Patients are followed every 4 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study within 10 months.

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Caen, France, 14076
        • Centre Regional Francois Baclesse
      • Dijon, France, 21000
        • Hopital Drevon
      • La Rochelle, France, 17000
        • Hopital Saint - Louis
      • Le Mans, France, 72000
        • Centre Jean Bernard
      • Lyon, France, 69008
        • Clinique Saint Jean
      • Metz, France, 57038
        • Hopital Notre-Dame de Bon Secours
      • Montfermeil, France, 93370
        • Intercommunal Hospital
      • Mulhouse, France, 68051
        • Centre Hospitalier de Mulhouse
      • Paris, France, 75970
        • Hôpital Tenon
      • Paris, France, 75475
        • Hôpital Saint-Louis
      • Senlis, France, 60309
        • C.H. Senlis
      • Suresnes, France, 92151
        • Centre Medico-Chirurgical Foch

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed colorectal adenocarcinoma

    • Clinical stage T3, T4, N+
  • Measurable disease
  • Awaiting surgery and likely to benefit from neoadjuvant radiotherapy

PATIENT CHARACTERISTICS:

Age

  • 18 to 80

Performance status

  • ECOG 0-2 OR
  • Karnofsky 60-100%

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 2.5 times ULN
  • No hepatic condition that would interfere with study medication

Renal

  • Creatinine clearance at least 80 mL/min
  • No renal condition that would interfere with study medication

Cardiovascular

  • No serious cardiac failure with the past year
  • No myocardial infarction within the past year
  • No cardiac insufficiency
  • No angina
  • No uncontrolled arrhythmia
  • No uncontrolled hypertension

Gastrointestinal

  • No superior intestinal tract malfunction
  • No malabsorption syndrome

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No concurrent serious infection
  • No other serious illness
  • No other malignancy within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix
  • No metabolic condition that would interfere with study medication
  • No dementia or altered mental status
  • No psychiatric illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior chemotherapy for colorectal cancer

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy for colorectal cancer

Surgery

  • Not specified

Other

  • More than 30 days since prior participation in another clinical study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Masking: NONE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Objective tumor response rate

Secondary Outcome Measures

Outcome Measure
Tolerability
Rate of preservation of functional integrity of the anal sphincter
Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Investigators

  • Olivier Dupuis, MD, Centre Jean Bernard

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2002

Study Registration Dates

First Submitted

January 9, 2004

First Submitted That Met QC Criteria

January 11, 2004

First Posted (ESTIMATE)

January 12, 2004

Study Record Updates

Last Update Posted (ESTIMATE)

February 9, 2009

Last Update Submitted That Met QC Criteria

February 6, 2009

Last Verified

May 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000346895
  • FRE-GERCOR-R01-01
  • EU-20329

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe